Biogen (BIIB) Total Current Liabilities (2009 - 2026)

Biogen (BIIB) has reported Total Current Liabilities for 18 consecutive years, with $3.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 43.39% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (down 43.39% YoY), while the FY2025 annual figure was $3.3 billion, down 39.42% from the prior year.
• Total Current Liabilities came in at $3.0 billion for Q1 2026 at Biogen, down from $3.3 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $5.5 billion in Q4 2024, with the low at $3.0 billion in Q1 2026.
• Average Total Current Liabilities over 5 years is $3.9 billion, with a median of $3.3 billion recorded in 2025.
• Across the five-year window, Total Current Liabilities jumped 64.37% in 2025 and plunged 43.39% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $3.3 billion in 2022, then advanced by 4.93% to $3.4 billion in 2023, then jumped by 60.99% to $5.5 billion in 2024, then tumbled by 39.42% to $3.3 billion in 2025, then declined by 10.46% to $3.0 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $3.0 billion, $3.3 billion, and $3.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.